When should we consider allo-HSCT in a patient with ALL? And when not?

During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, PL. We asked, When should we consider allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a patient with ALL? And when not?

Allo-HSCT is a very effective method of treatment for ALL, however, it is also associated with a significant risk of mortality. In this video, Giebel discusses tailoring treatment paradigms according to Philadelphia chromosome subtypes and high-risk karyotypes. He also touches upon ongoing studies looking at second- or third-generation tyrosine kinase inhibitors and chimeric antigen receptor (CAR) T-cell therapies that could offer new opportunities for patients with ALL in the future.